Navigation Links
Advanced Life Sciences to Present at Biodefense Session of 26th Annual JPMorgan Healthcare Conference

CHICAGO, Jan. 3 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation, today announced that it will present and participate in a panel discussion during a special session of the of 26th Annual JPMorgan Healthcare Conference on January 9, 2008.


The Company's presentation will be delivered during a special Biodefense Session hosted by JPMorgan and McKenna Long & Aldridge at 5:00 pm Pacific Time in the St. Francis Suite on the 12th floor of the Westin St. Francis hotel in San Francisco, CA. The presentation will focus on the Company's pre-NDA antibiotic, cethromycin, and its application as a biodefense countermeasure. The panel will discuss public health preparedness issues.

The program includes co-keynote addresses by:

-- Dr. Rajeev Venkeyya, Special Assistant to the President and Senior

Director for Biodefense at the White House Homeland Security Council

-- Brian Kamoie, Deputy Assistant Secretary Director, Office of Policy,

Strategic Planning & Communications Office of the Assistant Secretary

for Preparedness and Response U.S. Department of Health & Human


Following the Company's presentation and participation on the biodefense panel, there will be a question and answer session led by the moderator with audience participation.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections such as community acquired pneumonia (CAP). In addition to its utility in CAP, cethromycin is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure. The FDA has designated cethromycin as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, but the drug is not yet approved for this or any other indication. For more information, please visit us on the web at

Forward-Looking Statements

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
2. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
3. Advanced Life Sciences Enters Into Definitive Securities Purchase Agreements for $20 Million with New and Existing Institutional Investors
4. Young Physicians Demanding Advanced Laparoscopic Energy Instruments
5. Model for the assembly of advanced, single-molecule-based electronic components developed at Pitt
6. EDDA Technology Introduces Universal Enterprise Solution - Enabling 2D/3D/4D Advanced Clinical Applications on Existing PACS Workstations
7. Advanced Instruments Acquires Mart Microbiology B.V.
8. Advanced Life Sciences Announces Third Quarter 2007 Financial Results
9. Center for Molecular Medicine One of the First Midwest Labs to Offer Advanced Test for Patients with Metastatic Breast Cancer
10. Advanced Life Sciences to Host Third Quarter 2007 Financial Results Conference Call and Live Webcast
11. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Post Your Comments:
(Date:11/24/2015)... DIEGO , Nov. 24, 2015 Halozyme Therapeutics, Inc. ... Healthcare Conference in New York on Wednesday, ... Helen Torley , president and CEO, will provide a corporate ... New York at 1:00 p.m. ET/10:00 a.m. PT ... and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... ... ... The Academy of Model Aeronautics (AMA), led by its Executive Council, has officially ... to represent the First–Person View (FPV) racing community. , FPV racing has exploded in ... racing and several new model aviation pilots have joined the community because of their ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna ... announced today that the remaining 11,000 post-share consolidation ... Purchase Warrants (the "Series B Warrants") subject to ... exercised on November 23, 2015, which will result ... After giving effect to the issuance of such ...
Breaking Biology Technology:
(Date:10/26/2015)... , October 26, 2015 /PRNewswire/ ... --> adds Biometrics ... to 2021 as well as Emerging ... research reports to its collection of ... . --> ...
(Date:10/23/2015)... 23, 2015 Research and Markets ( ... Voice Recognition Biometrics Market 2015-2019" report to their ... The global voice recognition biometrics market to grow ... --> --> The report, ... based on an in-depth market analysis with inputs from ...
(Date:10/22/2015)... JOSE, Calif., Oct. 22, 2015  Synaptics (NASDAQ: SYNA ), ... for its first quarter ended September 30, 2015. ... quarter of fiscal 2016 grew 66 percent over the comparable quarter ... of fiscal 2016 was $23.8 million, or $0.62 per diluted share. ... income for the first quarter of fiscal 2016 grew 39 percent ...
Breaking Biology News(10 mins):